BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9581866)

  • 1. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
    J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD; Gleave ME
    Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
    Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
    Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
    Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
    Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
    Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.